PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin agonist with selective activity at MC3R and MC4R subtypes. Its stable ring structure — formed by a Glu4-Lys7 lactam bridge — confers exceptional metabolic stability in neuronal cell model conditions, enabling defined pharmacological characterisation across MC4R binding, signalling, receptor regulation, and hypothalamic neuropeptide pathway studies.

MC4R Binding and Receptor Selectivity Profile

Comprehensive MC receptor subtype binding profiling across MC1R, MC2R, MC3R, MC4R, and MC5R in recombinant HEK293 cell membrane preparations establishes PT-141's receptor selectivity landscape. High-affinity binding at MC3R and MC4R with nanomolar Ki values, substantially reduced affinity at MC1R and MC5R, and absent MC2R activity (ACTH receptor) define the selectivity profile. These data confirm that PT-141's neuronal pharmacology is mediated through MC3R and MC4R rather than through the pigmentation-associated MC1R or adrenocortical MC2R subtypes.

Constitutive MC4R Activity and Inverse Agonism

MC4R exhibits significant constitutive Gs activity in the absence of agonist — approximately 20–30% of maximal receptor activity — making PT-141 agonism characterisation dependent on accurate measurement of basal cAMP levels. In HEK293-hMC4R stable cell lines, HTRF cAMP assays with phosphodiesterase inhibitor IBMX pre-treatment establish basal cAMP, PT-141-stimulated cAMP, and maximal NDP-alpha-MSH-stimulated cAMP references. Inverse agonist AgRP(83-132) establishes the minimum activity floor, providing the full activity range for PT-141 intrinsic efficacy calculation.

Concentration-Response Characterisation

Eight-point concentration-response studies across 0.01 nM–1 µM PT-141 in MC4R-expressing neuronal cell lines establish EC50, Hill slope, and Emax parameters for cAMP accumulation, ERK1/2 phosphorylation, and beta-arrestin 2 recruitment in parallel assay formats. Operational model of agonism analysis quantifies transduction coefficients (log(tau/KA)) for each signalling pathway, enabling pathway-specific potency comparison and biased agonism quantification relative to the reference agonist NDP-alpha-MSH. These multi-pathway concentration-response data provide comprehensive MC4R pharmacology characterisation in neuronal cell models.

Hypothalamic Cell Model Signalling Studies

GT1-7, mHypoE-N44, and mHypoE-N46 hypothalamic neuronal cell lines provide physiologically contextualised MC4R pharmacology systems. Endogenous MC4R expression in these cell lines supports studies without overexpression artifacts, though expression verification by western blot and flow cytometry is prerequisite. Electrophysiology-relevant calcium oscillation recordings in GT1-7 cells following PT-141 treatment characterise neuronal excitability modulation downstream of MC4R activation, providing data complementary to biochemical signalling endpoint assays in hypothalamic model research.

Cross-Talk with Neuropeptide Y and POMC Pathways

MC4R activation by PT-141 in hypothalamic cell models modulates transcriptional output across the melanocortin-neuropeptide regulatory network. NPY and AgRP (endogenous MC4R inverse agonists) expression profiling by quantitative PCR following PT-141 treatment characterises negative feedback on orexigenic pathway gene expression. POMC-derived peptide processing enzyme (PC1/3, PC2, CPE) expression analysis establishes whether MC4R activation modulates endogenous melanocortin peptide biosynthesis capacity in hypothalamic cell model systems.

Metabolic Stability in Neuronal Cell Model Conditions

PT-141 stability in neuronal cell culture media (neurobasal medium, DMEM, serum-supplemented conditions) is characterised by HPLC-MS/MS quantification of intact compound over 0–240 minute incubation intervals at 37°C. Comparison with linear alpha-MSH analogues confirms the stability advantage of the cyclic lactam structure in protease-containing cell culture environments. These stability data establish valid concentration ranges and exposure durations for PT-141 neuronal cell model pharmacology protocols.

Research Summary

PT-141 demonstrates defined nanomolar MC3R/MC4R binding, constitutive activity-aware cAMP pharmacology, multi-pathway concentration-response characterisation, and hypothalamic neuropeptide network engagement in neuronal cell model preparations. Its characterised receptor selectivity, metabolic stability in neuronal conditions, and comprehensive signalling profile establish it as a reference melanocortin agonist for in vitro MC4R pharmacology and hypothalamic neuronal cell biology research.

All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.